Skip to content

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01019148
Enrollment
70
Registered
2009-11-25
Start date
2009-11-10
Completion date
2029-12-31
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis Bullosa Dystrophica

Brief summary

Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.

Detailed description

We will obtain a detailed medical history and will perform a skin examination and brief physical exam. Photographs may be taken. We will ask questions about the size and duration wounds. LAB TESTS We will draw blood to determine overall health status to include Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus (HIV) testing. Genetic testing may also be performed. BIOPSIES Biopsies may be collected to check for Collagen 7 and for antibodies to Collagen 7. Based on the results obtained, it may be possible to identify patients who would qualify to participate in current or future clinical trials.

Interventions

None listed

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of RDEB by local dermatologist * 7 years of age or older

Exclusion criteria

-Medical instability limiting ability to travel to Stanford University Medical Center

Design outcomes

Primary

MeasureTime frameDescription
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa10 yearsIdentification of subjects with Recessive Dystrophic Epidermolysis Bullosa for future studies

Countries

United States

Contacts

CONTACTIrene Bailey-Healy
baileyhi@stanford.edu(650) 721-7149
PRINCIPAL_INVESTIGATORJean Tang, MD, PhD

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026